Suzhou Connect Biopharma Co. Ltd.

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma – – Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma – – Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26 – SAN DIEGO, CA, USA I June 13, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. “The data being presented today at EAACI continues to demonstrate the potential of rademikibart to deliver best-in-class efficacy for asthma patients,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “Building on the previously reported data from our Phase 2b asthma study, these analyses highlight rademikibart’s capability to not only rapidly deliver improvements in lung function, but also significantly reduce annualized asthma exacerbation rates, particularly in those with high eosinophil and fractional exhaled nitric oxide or FeNO counts, key markers of type 2 inflammation. We believe these findings continue to bolster support for our rapid Phase 2 clinical development plan and we look forward to reporting topline data from our parallel Seabreeze STAT studies in the first half of 2026.” Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001678 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13 th from 3:00 p.m. – 4:30 p.m. BST Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001671 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13 th from 3:00 p.m. – 4:30 p.m. BST The presentations are available on Connect’s website under the presentations and publications section . About Connect Biopharma and Rademikibart Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV 1 ), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com . SOURCE: Connect Biopharma

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details are as follows: Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001671Presenter: Rekha Chaudhuri, M.D.Session Title: Clinical Trials on Airways DiseasesDate and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001678Presenter: Rekha Chaudhuri, M.D.Session Title: Clinical Trials on Airways DiseasesDate and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST Following the presentations, each presentation will be available on Connect’s website under the presentations and publications section. About Connect Biopharma and RademikibartConnect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com. Investor Relations Contact: Alex Lobo Precision AQ Alex.lobo@precisionaq.com (212) 698-8802 Media Contact: Ignacio Guerrero-Ros, Ph.D., or David SchullRusso Partners, LLCIgnacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 or (646) 942-5604

– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα ) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, CA, USA I May 20, 2025 I Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced clinical and preclinical data supporting rademikibart, the Company’s next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody, which was presented at the American Thoracic Society (ATS) 2025 International Conference, taking place from May 18-21, 2025, in San Francisco. “We are pleased to share new clinical and preclinical data highlighting rademikibart’s potential as a best-in-class treatment for patients with asthma or COPD experiencing an acute exacerbation,” said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. “The new analyses from our previously completed Phase 2b study not only demonstrate rademikibart’s rapid onset of action and significant improvement in lung function, but also further differentiate its safety profile, overcoming limitations of existing IL-4Rα inhibitors on the market. Taken together, these data reinforce our confidence in our clinical development plan and provide strong commercial rationale for rademikibart as a potentially superior next-generation IL-4Rα inhibitor.” Title: Rapid Improvement in Lung Function Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma Title: Efficacy of Rademikibart in COPD-like Patients: Sub-analyses From the Phase 2b Trial in Patients with Moderate-to-Severe Asthma Title: Effect of Rademikibart on Blood Eosinophil Counts in Patients with Asthma: Is There an IL-4Rα Class Effect? Title: Optimized Second-generation IL-4Rα Inhibition: Structural and Molecular Dynamics Properties of Rademikibart Fab-IL-4Rα Complex The poster presentations will be available on Connect’s website under the Presentations and Publications section . About Connect Biopharma and Rademikibart Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV 1 ), observed within one week—and in most cases, within 24 hours via home spirometry. For more information visit www.connectbiopharm.com . SOURCE: Connect Biopharma